Breathtec Announces Name Change to Algernon Pharmaceuticals
February 14 2019 - 7:00AM
Breathtec Biomedical Inc. (CSE: BTH) (CNSX: BTH)
(FRANKFURT: BTI) (OTCQB: BTHCF) (the
“
Company” or “
Breathtec”) is
pleased to announce that as a result of the strength of the data
from its Nash Pharmaceuticals pre-clinical research program, it
will be changing its name to Algernon Pharmaceuticals Inc.
The change will take place before market opens
on February 19, 2019 and the Company's ticker symbol will change
from "BTH to "AGN" on the Canadian Securities Exchange. Changes to
the symbol for the Frankfurt and OTCQB exchanges are in progress
and the Company will provide an update on the new symbols shortly.
The Company’s new website will also be activated on February 19,
2019 and can be found at www.algernonpharmaceuticals.com.
The name Algernon was inspired in part, by the
Hugo Award winning, 1959 science fiction short story “Flowers for
Algernon”, which was a story about change and transition.
“We are very pleased to be moving forward with
our corporate rebranding,” said Christopher J. Moreau, CEO of
Algernon Pharmaceuticals Inc. “Based on the success of our
pre-clinical drug development program, we believe that this change
will help to communicate to the market, our excitement and
confidence in our newly established drug research program.”
About Algernon Pharmaceuticals
Inc.
Algernon Pharmaceuticals is a clinical stage
pharmaceutical development company focused on advancing its lead
compounds for of non–alcoholic steatohepatitis (NASH), chronic
kidney disease (CKD) and inflammatory bowel disease (IBD).
CONTACT INFORMATION
Christopher J. Moreau CEOAlgernon Pharmaceuticals
Inc.604.398.4175 ext 701info@breathtechbiomedical.com
investors@breathtecbiomedical.com www.breathtecbiomedical.com
The CSE does not accept responsibility
for the adequacy or accuracy of this release.
Neither the Canadian Securities Exchange
nor its Market Regulator (as that term is defined in the policies
of the Canadian Securities Exchange) accepts responsibility for the
adequacy or accuracy of this release. The Canadian Securities
Exchange has not in any way passed upon the merits of the proposed
transaction and has neither approved nor disapproved the contents
of this press release.
CAUTIONARY DISCLAIMER STATEMENT: No Securities
Exchange has reviewed nor accepts responsibility for the adequacy
or accuracy of the content of this news release. This news release
contains forward-looking statements relating to product
development, licensing, commercialization and regulatory compliance
issues and other statements that are not historical facts.
Forward-looking statements are often identified by terms such as
“will”, “may”, “should”, “anticipate”, “expects” and similar
expressions. All statements other than statements of historical
fact, included in this release are forward-looking statements that
involve risks and uncertainties. There can be no assurance that
such statements will prove to be accurate and actual results and
future events could differ materially from those anticipated in
such statements. Important factors that could cause actual results
to differ materially from the Company’s expectations include the
failure to satisfy the conditions of the relevant securities
exchange(s) and other risks detailed from time to time in the
filings made by the Company with securities regulations. The reader
is cautioned that assumptions used in the preparation of any
forward-looking information may prove to be incorrect. Events or
circumstances may cause actual results to differ materially from
those predicted, as a result of numerous known and unknown risks,
uncertainties, and other factors, many of which are beyond the
control of the Company. The reader is cautioned not to place undue
reliance on any forward-looking information. Such information,
although considered reasonable by management at the time of
preparation, may prove to be incorrect and actual results may
differ materially from those anticipated. Forward-looking
statements contained in this news release are expressly qualified
by this cautionary statement. The forward-looking statements
contained in this news release are made as of the date of this news
release and the Company will update or revise publicly any of the
included forward-looking statements as expressly required by
applicable law.
Breathtec BioMedical Inc. (CSE:BTH)
Historical Stock Chart
From Jan 2025 to Feb 2025
Breathtec BioMedical Inc. (CSE:BTH)
Historical Stock Chart
From Feb 2024 to Feb 2025